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Molecule synthesis and characterization
S1.1 Chemicals
All amino acids were purchased from AAPPTEC (Louisville, KY). Rink Amide MBHA Resin was purchased from NovaBiochem (San Diego, CA). Paclitaxel was from Ava Chem Scientific (San Antonio, TX), 4-bromobutyric acid and thiourea were purchased from Sigma-Aldrich (St. Louis, MO). N,N'-diisopropylcarbodiimide (DIC) and 4-dimethylaminopyridine (DMAP) were obtained from TCI, and all other reagents and solvents were sourced through VWR.
S1.2 AcCGVQIVYKK peptide synthesis
The peptide AcCGVQIVYKK was synthesized using AAPPTEC Focus XC synthesizer via standard Fmoc-solid phase technique. Fmoc groups were deprotected using 20% 4-methylpiperidine in DMF, and amino acid/HBTU/DIEA (4/3.98/6) was applied for coupling.
The N-terminal amine was acetylated manually by reacting with 20% acetic anhydride in DMF. 
S1.3 4-(pyridin-2-yldisulfanyl) butyric acid synthesis
4-Bromobutyric acid (2g, 12mmol) and thiourea (0.96 g, 12.6 mmol) were dissolved in ethanol (50 mL) and refluxed at 90 °C for 4 h. After dropwise addition of a NaOH solution (4.8 g in 5:1 H 2 O/ethanol), the mixture was refluxed for another 16 h and then cooled to room temperature. The white precipitate was collected and redissolved in water (40 mL). 4 M HCl was used to adjust the solution pH to 5, and the product was extracted into diethyl ether. The organic phase was dried over anhydrous sodium sulfate to give 4-sulfanylbutyric acid as a colorless oil (310 mg, 15%), which was used in the next step without further purification. 4-sulfanylbutyric acid (105 mg, 0.87 mmol) and 2-aldrithiol (440 mg, 2.0 mmol, 2.3 eq) were dissolved in MeOH (1.3 mL) and stirred for 3 h. The solution was purified by RP-HPLC (5% to 95% of acetonitrile in water with 0.1% TFA over 45 min), combining product fractions and removing solvents to give 4-(pyridin-2-yldisulfanyl) butyric acid as an oil (118 mg, 59% 
S1.4 Paclitaxel C2' ester synthesis
Paclitaxel C2' ester was synthesized using a previously published procedure.
1 Paclitaxel (186 mg, 0.22 mmol), 4-(pyridin-2-yldisulfanyl)butyric acid (100 mg, 0.44 mmol), DIC (68 μL, 0.44 mol), and DMAP(26.7 mg, 0.22 mmol) were added into an oven dried flask equipped with a stirrer bar, evacuated and refilled with nitrogen three times to remove air, then dissolved in anhydrous acetonitrile (12.7 mL). The reaction was allowed to stir in the dark at room temperature for 48 h. The solvents were removed in vacuo and the residue was dissolved in chloroform and purified by flash chromatography (3:2 EtOAc/ hexane), to give the product as a white solid (108 mg, 47% 
S1.5 PTX-Tau synthesis
AcCGVQIVYKK (27.7 mg, 25.7 mmol) and paclitaxel C2' ester (54.7 mg, 51.4 mmol) were added to an oven dried flask equipped with a stirrer bar and evacuated and filled with nitrogen three times to remove the air. The reagents were then dissolved in anhydrous DMF (5 mL). The solution was allowed to stir for 16 h, before purification by RP-HPLC (30% to 95% acetonitrile in water with 0.1% TFA over 45 min). Product fractions were combined and lyophilized to give a PTX-Tau as a white powder. (31 mg, 60% 
S2 Self-assembly characterization

S2.1 Transmission Electron Microscopy
All the self-assembly experiments were performed at room temperature. PTX-Tau conjugate was directly dissolved into deionized water to make solutions of desired concentrations. Solutions were typically aged for 48 h before TEM imaging. TEM samples were prepared by adding ~10 μL solution onto a carbon-film-coated copper grid. After careful removal of the excess liquid using a piece of filter paper, a drop of 2% w/v uranyl acetate aqueous solution (~10 μL) was added onto the TEM grid as a negative staining agent. Again, excess solution was removed using a piece of paper to result in a thin film on the grid that was allowed to air dry before imaging. A Technai12 TWIN transmission electron microscope was used to image the prepared samples operating typically at 100 kV, with images recorded by a SIS Megaview III wide-angle CCD camera.
S2.2 Circular Dichroism (CD) Spectroscopy
CD spectra were recorded on a Jasco J-710 spectropolarimeter (JASCO, Easton, MD) using a 10 mm pathlength Spectrasil® quartz UV-Vis absorption cell (Starna Cells Inc., Atascadero, CA). Data was normalized with respect to sample concentration (5 μM), path length, and the number of residues from the expected β-sheet forming segment.
S2.3 Fluorescence Spectroscopy
1 mM Nile Red stock solution was prepared in acetone and diluted 100-fold into PTX-Tau solutions of various concentrations. The acetone was allowed to evaporate and the samples were equilibrated overnight. 2 Emission spectra for each sample were then recorded on a Fluorolog spectrofluorometer (Horiba Jobin Yvon Inc., Edison, NJ) between 580 and 720 nm, with an excitation wavelength of 550 nm.
S3 AFM and cryo-TEM images of PTX-Tau filaments
The morphology of the observed supramolecular filaments formed by self-assembly of PTX-Tau conjugate was further confirmed using atomic force microscopy (AFM) and cryogenic transmission electron microscopy (cryo-TEM). The release characteristics of the conjugate were studied at two concentrations, 5 and 100 μM. Briefly, a 20 mM glutathione stock solution was prepared in 20 mM PBS buffer (pH 7.4), while solutions of conjugate (10 and 200 μM) were prepared in water. Equal volumes of conjugate and GSH solution were then mixed to reach a final GSH concentration of 10 mM, and the mixture solution were incubated at 37°C for the desired periods of time (total 48 hours). Samples were taken at predetermined time points (0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48 h) and release of paclitaxel from conjugate was detected by HPLC. 2 ×PBS buffer was used to prepare the negative controls containing no GSH. 
S5.2 Cell viability study of PTX-Tau amphiphile
The cytotoxicity of PTX-Tau was determined using a dose-response study. A 24-well plate was seeded with cell sat a density of 10 5 cells/well and incubated at 37 °C for 24 h. The cells were then treated with varying concentrations of paclitaxel or conjugate in cell medium and incubated for a further 48 h. Cell viability was determined by sulforhodamine-B (SRB, Sigma Aldrich) assay according to the manufacturer's protocol. The data was fitted using the Hill equation function within the Igor Pro program and used to obtain the IC 50 values. cells were plated onto a collagen-coatedsterile glass coverslip and incubated for 24 h. Cells were treated with 50 nM paclitaxel or PTX-Tau, using DMSO as a negative control. After incubating for 48 h, cells were washed with D-PBS buffer, stained with a solution containing 2 μM calcein AM and 4 μM EthD-1, and then imaged using fluorescence microscopy (JENCO, OR).
